Oramed Pharmaceuticals Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins

//Oramed Pharmaceuticals Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins

Oramed Pharmaceuticals Granted Israeli Patent for Its Core Technology in Oral Delivery of Proteins

JERUSALEM–(BUSINESS WIRE)–May. 16, 2012–
Marking a major milestone for the company, Oramed Pharmaceuticals Inc.
(OTCBB:ORMP) (www.oramed.com),
a developer of oral drug delivery systems, announced today that it has
received approval for a key patent by the Israeli Patent Office. The
patent, entitled “Methods and Compositions for Oral Administrations of
Proteins,” covers a central facet of the company’s core
technology. Oramed’s portfolio now consists of two issued patents and 35
patents pending for its technologies and products.

Nadav Kidron, CEO of Oramed, commented: “The acceptance of our first
Israeli patent is a great accomplishment for Oramed, as this patent
covers a fundamental aspect of our technology. Its approval, along with
the recent approval of the same patent in Australia, will help pave the
way to further validations of our technology. We expect more patents to
be approved in the near future, thus establishing the company’s name as
one synonymous with innovation.”

An oral delivery system for current injectable-only medications – such
as vaccinations, insulin, GLP-1 analog, and others – may increase
patient compliance thus leading to a more favorable prognosis in the
condition being treated, as well as reducing overall costs to the
healthcare system in the long run.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral
delivery solutions for drugs and vaccines currently delivered via
injection. Established in 2006, Oramed’s technology is based on over 25
years of research by top research scientists at Jerusalem’s Hadassah
Medical Center
. Oramed is seeking to revolutionize the treatment of
diabetes through its patented flagship product, an orally ingestible
insulin capsule currently in Phase 2 clinical trials, and with its GLP-1
analog capsule, currently entering Phase 2a trials. The company’s
corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press
release, please visit
www.oramed.com.

Safe Harbor for Forward-Looking Statements: This press release
contains forward-looking statements. For example, we are using
forward-looking statements when we discuss our expectations for
additional patents, our technologies and their validation and the
possibility of increased patient compliance and lower healthcare costs
resulting from our products. These forward-looking statements are based
on the current expectations of the management of Oramed only, and are
subject to a number of factors and uncertainties that could cause actual
results to differ materially from those described in the forward-looking
statements, including the risks and uncertainties related to the
progress, timing, cost, and results of clinical trials and product
development programs; difficulties or delays in obtaining regulatory
approval or patent protection for our product candidates; competition
from other pharmaceutical or biotechnology companies; and our ability to
obtain additional funding required to conduct our research, development
and commercialization activities. In addition, the following factors,
among others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology and
market requirements; delays or obstacles in launching our clinical
trials; changes in legislation; inability to timely develop and
introduce new technologies, products and applications; lack of
validation of our technology as we progress further and lack of
acceptance of our methods by the scientific community; inability to
retain or attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties that may
develop with our process; greater cost of final product than
anticipated; loss of market share and pressure on pricing resulting from
competition; laboratory results that do not translate to equally good
results in real settings; our patents may not be sufficient; and finally
that products may harm recipients, all of which could cause the actual
results or performance of Oramed to differ materially from those
contemplated in such forward-looking statements. Except as otherwise
required by law, Oramed undertakes no obligation to publicly release any
revisions to these forward-looking statements to reflect events or
circumstances after the date hereof or to reflect the occurrence of
unanticipated events. For a more detailed description of the risks and
uncertainties affecting Oramed, reference is made to Oramed’s reports
filed from time to time with the Securities and Exchange Commission.

Source: Oramed Pharmaceuticals Inc.

Company and Investor Relations Contact:
Oramed Pharmaceuticals Inc.
Aviva
Sherman
USA: +1 646-240-4193
Int’l: + 972-2-566-0001
+
972-54-792-4438
aviva@oramed.com

2018-05-30T17:04:47+00:00 Categories: Press Releases|Tags: |